UK drugmaker Shire has withdrawn 39 lots of Daytrana (methylphenidate transdermal system) for attention-deficit hyperactivity disorder because some of the patches no longer meet their release liner removal specification and, as a result, patients and caregivers could have difficulties removing the liners.
Shire stressed that its action is not due to safety issues and noted that Daytrana patches, including those in the lots withdrawn, can continue to be used unless the release liner cannot be removed, or the patches are damaged while being opened.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze